Member Info for Aether

A TO or JV are the most likely ways to extricate from the share.

Our immediate hopes rest on:

- getting on another trial(s). You are right a large enough trial is critical.
- SPRINTER P3 deep dive and long Covid analysis throw up some gems.
- ACTIV-2 P2 data being very good.
- Long Covid data.

The drug works.

Patience is key.

If any of the above occurs, Poly will not be idle and wait for another trial.

If the data contains any gems and shows it can be brought to market, it can be sold.

It can be sold at a reasonable price to a larger pharmaceutical company. No waiting for more trials.

Again, Poly will be a potentially important safeguard to ensure a reasonable price.

Our immediate hopes rest on:

- getting on another trial(s).
- SPRINTER P3 deep dive and long Covid analysis throw up some gems.
- ACTIV-2 P2 data being very good.
- Long Covid data.

The drug works.

Patience is key.

If any of the above occurs, Poly will not be idle and wait for another trial.

Our immediate hopes rest on:

- getting on another trial(s).
- SPRINTER P3 deep dive and long Covid analysis throw up some gems.
- ACTIV-2 P2 data being very good.
- Long Covid data.

The drug works.

Patience is key.

If any of the above occurs, Poly will not be idle and wait for another trial.

We are all hoping the Long Covid results from SPRINTER are significant.

It would be a massive boost to EUA success.

This thread is FUBAR.

Certain posters only want to derail discussion of his company.

Green button them.

Done.

A few LT holders have stated a price above £1 to £1.5. That is the price I would sell at. 80p would be pushing it.
Below that, it is not worth selling.

This has become a very stressfull share to hold. Peace.

If the data is good?

£1+

Why the low ball figure? Why would Poly allow it?

It's a possible scenario, FTC7.

It is unlikely though given all the research. The real danger is if the data is average.

The long covid and progression to death data is critical.

"Furthermore, if our Long Covid results are significant then the odds are very much in our favour.....The costs of treating Long Covid are going to be billions..."

This and the progression to death data are critical.

If these are successful, there will be interest from a Big Pharma.

The quickest way to extricate from this share is a TO by a larger pharmaceutical company.

What are the options for Polygon?

"2). Sprinter deep dive analysis and Activ 2 data is okay, but doesn't merit a EUA application. It is good enough to generate enough interest that Synairgen is sold off to a big pharmaceutical. Under this scenario Polygon are highly influential. Maybe you break even, maybe you make a 2 or 3x EM.. some long term holders will do very well, but I would envisage the company is sold off in the 150 to 300 gbx range. Maybe even lower. However, I think the strike price will be above Polygons average."

Yes. Excellent post.

If the deep dive data and ACTIV-2 P2 data are good but don't result in a EUA application.
Could a larger pharmaceutical company still TO the company for the IP so they can bring the product to market?

"The detection of these auto-Abs before the occurrence of disease may lead to specific measures being taken, ... , or early treatment with exogenous recombinant cytokines (e.g., IFN-ß) following infection, as exemplified by COVID-19 (Vinh et al., 2021)."

The most effective treatment options are being discerned and IFN-ß is one of them.

At some point, a Big Pharma will make a move, especially if the Deep Dive data is good.

Is it a personality disorder that's causing this behaviour? I can't see them as a professional deramper.

If the sp rises to 80 to 100p, I'm out.

That would value the company up to £200,000,000.

Our immediate hopes rest on:

- getting on another trial(s).
- SPRINTER P3 deep dive and long Covid analysis throw up some gems.
- ACTIV-2 P2 data being very good.

This is now about patience and waiting.

Other companies have been brought out and the larger company taken the drug to market.

SNG is an excellent drug. It will make money. The question is when.

Is it just housekeeping or does it have a real impact on our understanding of the clinical trial?

*bump*

Is it just housekeeping or does it have a real impact on our understanding of the clinical trial?